Skip to main content

Combination Therapies and New Molecular Targets—Presentations from AACR 2021

Conference Correspondent
David Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.

Related Items